Based in Lexington, Mass., the Cystic Fibrosis Foundation Therapeutics Lab conducts groundbreaking CF research to help rapidly advance new therapies.
Site Search
Cystic fibrosis occurs when the cystic fibrosis transmembrane conductance regulator (CFTR) protein is either not made correctly, or not made at all. By understanding how the protein is made, scientists have been able to develop treatments that target the protein and restore its function.
The journey to end cystic fibrosis isn't a straight line. It is an evolving map with many paths and unique challenges. It requires an ambitious research agenda to accelerate treatments and drug development for the underlying cause of the disease and ultimately deliver a cure.
Support our mission with a grant: We welcome support from private, corporate, and family foundations.
Once your
Choosing to volunteer in a
The CF Foundation is the world’s leader in the search for a cure for cystic fibrosis. We are dedicated to attacking CF from every angle. Help us by making a donation today. Every gift we receive – big or small – helps us get one step closer to finding a cure for cystic fibrosis.
By participating in one of our many fundraising events — or starting your own — you can bring together friends, family, and others you know to raise funds in support of the CF Foundation's mission: to find a cure for cystic fibrosis.
You're invited to join the 65 Roses® Club, a special group of Cystic Fibrosis Foundation donors dedicated to finding a cure for CF by providing monthly support. There are many benefits to becoming a member of the 65 Roses® Club, such as receiving a special biannual newsletter, IMPACT, our annual 65 Roses® calendar and exclusive invitations to your local chapter's events. Help accelerate progress and join today!
Clinical trials that test potential drugs and therapies in people with cystic fibrosis are a major part of CF research. They take place at Cystic Fibrosis Foundation-accredited care centers all over the United States and enroll people with CF of all ages.